We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Policy prescriptions are plentiful but momentum and money behind them is lacking
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Human life appears to have an upper limit that has yet to be extended
Manufacturers racing to build what could be one of industry’s biggest markets must tread with care
Alzheimer’s advocates call for ambitious declaration to match the scope of commitments made 10 years ago
Shadow health secretary sets out plan to boost clinical research
One in 5 biomedical articles may contain faked data, with Chinese paper mills leading way
In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide
Biggest biomedical charity makes first investment in science infrastructure from its endowment
Clinical study results could boost patient access to new class of treatment
Industry watchers say UK-listed rival AstraZeneca has a stronger pipeline and benefits from its oncology expertise
UK scientists carry out most comprehensive study so far of tumour evolution and its implications for treatment
Chief executive says draft plan to cut market exclusivity protection could make pursuing some treatments unviable
Swiss group rethinks NHS collaboration after low take-up of treatment during rollout via GPs
Companies want incentives to create jobs and stave off competition from China
MHRA chief in talks with watchdogs in Australia, Canada, Singapore and Switzerland to create partnership
A Nasdaq-listed company is trialling the active ingredient in magic mushrooms as a new treatment
High hurdles and pricing reforms mean companies will need ingenuity to achieve a premium
Some of the world’s biggest health challenges do not lend themselves to conventional investment
Pharma chief says sector is seen as ‘niche’ and leaves women suffering from healthcare inequality
Chief executive Paul Hudson sounds the alarm over British government’s cuts to research
UK biotech racing to keep antibody up to date with latest variants
Agreement is one of several announced as major healthcare conference begins in San Francisco
Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing
Success in battle against Covid does not ensure success against tumours, but should narrow the odds
UK Edition
